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The burden of disease for cholera remains high especially in low and lower middle 
income countries. Africa is the most affected by the disease among countries in this 
category. Severe outbreaks and persistent endemicity with high case fatality ratio (CFR) 
continue to rock the continent due to poor water and sanitation conditions. The outbreaks 
are also a result of prevailing internal and regional conflicts resulting to numerous 
Internally Displaced Persons (IDPs) and refugee camps which lack sufficient sanitation 
facilities. The epidemics are also attributable to perennial droughts and flooding during the 
rainy season in the region. Out of the 172,464 cholera cases reported to the WHO in 2015, 
the Africa region accounted for 55.8%. This study aims to estimate the economic burden 
of cholera in Africa in order for the respective countries to be appraised on the levels of 
preparedness that they require to put in place as well as allocate more resource in cholera 
prevention programs. 
  This was expressed by evaluating economic burden inputs such as cost of treatment 
borne by facilities, out-of-pocket expenditure, loss of productivity borne by individual 
families, from both patients and caregivers and cost effectiveness of interventions. The 
countries were classified by income level and based on the WHO mortality stratum. 
Reported cholera cases used in this analysis were derived from WHO reports in 2015. 
However, due to under-reporting by some countries due to fear of negative economic 
impact, cases estimated by a 2015 study on cholera burden by Ali et al were also utilized.  
xi 
Our analysis included 44 African countries where it was estimated to have a total of 
1,756,703 cholera cases and 66,416 deaths in 2015. In contrast, the WHO cholera report 
documented 16 countries with 71,176 cases and 937 deaths in Africa. Through this analysis 
we estimated $74.4 million (I$186.4 million) in out-of-pocket expenditure, US$104.2 
million (I$258.2 million) in public health sector costs and $54.0 million (I$131.9 million) 
in lost productivity of patients and caregivers. Lost productivity due to premature death due 
to cholera was estimated to be $1.6 billion (I$4.1 billion). The total economic burden of 
cholera in Africa was estimated at $1.9 billion (I$4.6 billion). 
Information on the estimation of the economic burden of cholera will give policy 
makers insight to make informed decisions in regard to prevention, detection, response and 




Cholera, an acute, diarrheal illness caused by infection of the intestine with the 
toxigenic bacterium Vibrio cholerae serogroup O1 or O139 [1], is one of the largest 
diarrheal illnesses in Africa due to poor water, sanitation and hygiene (WASH) conditions 
[2].  
Globally it is estimated that 2.8 million cholera cases occur annually in cholera 
endemic countries and 1.4 billion people are at risk. It is also estimated that 91,000 people 
die of the disease every year [3]. In 2015 172,454 worldwide cases were reported to the 
World Health Organization (WHO) of which 1,304  resulted in death [2]   
Table 1: Cholera case and deaths reported to WHO in 2015  
Region Cases Deaths 
Africa 71,176 937 
Asia 64,590 30 
Europe 22 0 
America 36,664 337 
Oceania 2 0 
Total 172,464 1304 
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African countries continue to experience cholera outbreaks over the years despite 
a concerted effort by their respective departments of health to curb the menace. This has 
resulted in a negative impact on the economies of these countries due to the high costs 
involved in the prevention, detection and response to these outbreaks [4]. While several 
studies have been done in various countries on economic burden of cholera, cost-
effectiveness of interventions among other areas of interest, there is a lack of an updated 
study to estimate the economic burden in Africa looking into the areas of loss of 
productivity, hospitalization and outpatient costs.  Diarrheal diseases, under which cholera 
is classified, are according to the World Health Organization (WHO)  ranked as the number 
two leading cause of premature deaths in low income countries [5]. 
 
Figure 1: Burden of disease for AFR region Source:WHO 
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Sub-Saharan Africa, according to Amber Hsiao et al, accounts for 60% of cholera 
cases. It would be necessary therefore, to determine the economic burden for purposes of 
planning  interventions  [3]. Our study aims to estimate the economic burden of cholera in 
Africa in order for the respective countries to appraise the level of preparedness as well as 
allocate more resource in cholera prevention programs and enable the readiness of managers 
to handle outbreaks effectively.  
Table 2: Cholera cases reported to the WHO in 2015 from the AFR region. Source: WHO 
Country  Cases  Deaths  CFR 
Burundi 442 0 00 
Cameroon 124 6 4.8 
Cote d’voire 199 6 3.0 
Congo DR 19,182 276 1.4 
Ghana 692 8 1.2 
Kenya 13,292 67 0.5 
Malawi 693 11 1.6 
Mozambique 8,739 64 0.7 
Niger 51 4 7.8 
Nigeria 5,290 186 3.5 
4 
Country  Cases  Deaths  CFR 
Somalia 7,536 84 1.1 
South Sudan 1,818 47 2.6 
Tanzania 11,563 144 1.2 
Togo 35 1 2.9 
Uganda 1,461 33 2.3  
Zimbabwe 60 0 0.0 
Total  71,176 937 1.3 
 
Literature review 
This section involves identifying the existing estimations of cost of illness and 
economic burden of cholera which will serve as the basis of this study by considering what 
other writers have contributed to the area of study. We will also provide a summary of the 
gaps identified in the studies at the end of the chapter.  
Economic burden of disease 
Morbidity and mortality are key considerations in estimating the economic burden 
of disease in populations, however it is not a reliable way of depicting the adverse impact 
caused by ill-health to human welfare, especially the economic consequences. According 
to the WHO, to be able to determine the economic consequences of disease or injury, we 
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must look at microeconomic level of households, firms or governments as well as the 
macroeconomic level which include the aggregate impact of a disease on a country’s 
current and future gross domestic product (GDP) [6]. Joses M Kirigia et al for example did 
a study whose objective was to estimate the direct and indirect cost of cholera in the WHO 
African Region [4]. They estimated that about 178,677 cases of cholera and 4,033 cholera 
deaths were notified to the WHO in 2007, of which 62% cases and 56.7% deaths were 
reported from the WHO African Region. 
The study used standard cost-of illness methods to estimate: (a) the direct costs, 
i.e. those borne by the health-care system and the family in directly addressing cholera; and 
(b) the indirect costs, i.e. loss of productivity caused by cholera, which is borne by the 
individual, the family or the employer and was based on the number of cholera cases and 
deaths notified to the WHO [4]. 
This study indicates that the economic burden of cholera in Africa was estimated 
to have an economic loss of US$39million, US$53.2million and US$64.2million using 
regional life expectancies of 40, 53 and 73 respectively [4]. 
Another study aimed to assess the costs of cholera illness and determine the cost-
effectiveness of the 2016 vaccination campaign in Zambia in 2006. This was following the 
introduction of a Shancol—an oral cholera vaccine (OCV) campaign by the Zambian 
Ministry of Health in response to a cholera outbreak [7]. 
A recent study has been done on economic burden of cholera in Asia. According 
to the study out-of-pocket expenditure was estimated at US$20.2 million (I$74.4 million), 
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public sector cost of about US$8.5 million (I$30.1 million), loss of productivity due to 
illness was estimated at $12.1 million (I$43.7 million) and lost productivity due to 
premature deaths was estimated to be $985.7 million (I$3,638.6 million) [8]. Since Africa 
and Asia do not have the same social economic characteristics, this study will provide more 
insight into comparing the situations in Asia and Africa on the economic burden of cholera. 
In another previous study conducted in Ghana, Dziedzom K.A et al did a household 
cost analysis and concluded that low income areas bear a higher household economic 
impact during cholera outbreaks [9]. Most African countries are in the category of low 
income and therefore our study will put into perspective the economic burden of cholera in 
the continent. 
Interventions  
To prevent and control cholera and to reduce cholera-related deaths a multifaceted 
approach is used. This includes surveillance, water, sanitation and hygiene, social 
mobilization, treatment, and oral cholera vaccines among others control measures[10]. 
Surveillance 
Information sharing at the global level and feedback at the community level should 
be used in integrated disease surveillance which include cholera surveillance.  
Detection of cholera cases is usually based on clinical suspicion in patients that present 
with watery diarrhea. Stool samples from affected patients are then tested for V. cholerae 
to confirm the suspicion. An effective surveillance system requires local laboratory 
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capacity in order to diagnose and monitor cholera occurrence which will be vital in 
planning for control measures. 
Cross border surveillance should be strengthened especially in countries that 
neighbour cholera affected areas to prevent the spread of the disease across borders and 
enhance national preparedness to rapidly detect and respond to any eventualities.  
Although notification of all cases of cholera is no longer mandatory under the 
International Health Regulations, public health events involving cholera must always be 
assessed against the criteria provided in the regulations to determine whether there is a need 
for official notification [10]. 
Vaccination 
In their study aims at estimating the cost-of-illness of cholera to households and 
health facilities in Machinga and Zomba Districts Malawi, IIbuodo PG, et al conducted a 
cross-sectional study using retrospectively collected cost data. In the study it is noted that 
the average costs to patients' households and health facilities for treating an episode of 
cholera was US $65.6 and US$59.7 in 2016 for households and health facilities, 
respectively which was equivalent to 249.9 and 227.5 international dollars(I$). Costs 
incurred in treating a cholera episode were proportional to duration of hospital stay. Also, 
52% of households used coping strategies to compensate for direct and indirect costs 
imposed by the disease. Broader use of pre-emptive cholera vaccination could avert 
significant treatment expenditures incurred by households and health facilities through. 
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These findings have direct policy implications regarding priority investments for the 
prevention and control of cholera [11]. 
Oral cholera vaccines (OCVs) 
There are three oral cholera vaccines that are currently pre-qualified by WHO. 
These are Dukoral®, Shanchol™, and Euvichol®. For full protection all 3 vaccines require 
2 doses [10]. 
Dukoral® is administered with a buffer solution that, for adults, requires 150 ml of 
clean water. It is therefore recommended for travelers as access to clean water is often 
limited in areas with cholera epidemics. Dukoral® provides about 65% protection against 
cholera for 2 years [10]. The other two vaccines Shanchol™ and Euvichol® are essentially 
similar vaccine from two different companies. Since they do not require a buffer solution 
to administer, they are recommended for use in emergencies where many people need to 
be vaccinated. 1 dose of vaccine will provide some protection with the second dose given 
at a later date A minimum of a two-weeks delay between each dose of these 2 vaccines 
must be allowed. [10]. 
The vaccine gives approximately 65% protection against cholera for up to 5 years 
to vaccinated individuals. Herd protection is also attained through the reduction of V. 
cholerae bacteria circulation in the population as a result of vaccination in  endemic areas. 
[10]. 
The WHO has established a stockpile of 2 million doses for use in outbreak control 
and emergencies since 2013. The stockpile is managed by the International Coordinating 
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Group (ICG) made up of the International Federation of Red Cross and Red Crescent 
Societies, Medecins Sans Frontieres, UNICEF, and WHO [10]. 
For non-emergency settings, vaccines are available via the Global Task Force on 
Cholera Control (GTFCC). In these contexts, oral cholera vaccines are used as part of a 
longer-term cholera control plan including reinforcement of other aspects of cholera control 
such as improvements in water and sanitation. In eligible countries, financial support for 
vaccines is provided by Gavi, the Vaccine Alliance (GAVI) [10]. 
More than 5 million doses of OCVs have been used in mass vaccination campaigns 
with WHO support. The campaigns have been implemented in areas experiencing an 
outbreak in areas at heightened vulnerability during humanitarian crises, and among 
populations living in highly endemic areas, known as “hotspots” [10]. 
The use of OCVs has enabled the collection of evidence on and demonstration of 
the effectiveness and feasibility of implementing OCV campaigns as a public health tool, 
protecting populations at high risk of cholera [10]. 
WASH  
Economic development and universal access to safe drinking water and adequate 
sanitation facilities offers long-term solution for cholera control. Implementation of 
sustainable WASH solutions in cholera hotspots are important actions targeting 
environmental conditions. Other than cholera, these WASH measures prevent a wide range 
of other water-borne illnesses, as well as aiding to achieve goals related to poverty, 
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malnutrition, and education.  WASH goals are anchored in many ways to the targets of the 
Sustainable Development Goals (SDGs) [10]. 
SDG goal number six aims to “ensure availability and sustainable management of 
water and sanitation for all” UNICEF has undertaken three main targets under WASH: (a), 
to achieve universal and equitable access to safe and affordable drinking water for all by 
the year 2030. (b), to achieve adequate and affordable access to proper sanitation and 
hygiene and end open defecation and paying special attention to the needs of girls and 
women in vulnerable situations by 2030, and (c), improve water quality by reducing 
pollution, eliminating dumping and minimizing release of hazardous chemicals and 
materials, halving the proportion of untreated wastewater and substantially increasing 
recycling and safe reuse globally by the year 2030 [12].  
Treatment  
Cholera can be treated easily through prompt administration of oral rehydration 
solution (ORS). The WHO/UNICEF ORS standard sachet is dissolved in 1 litre (L) of clean 
water. Adult patients may require up to 6 L of ORS to treat moderate dehydration on the 
first day [10]. 
Rapid administration of intravenous fluids is required for severely dehydrated 
patients who are at risk of shock. For example, an adult who weighs 70 kg will require at 
about 7 litres of intravenous fluid, in addition to ORS during the treatment. Antibiotics are 
also given appropriately to reduce the duration of diarrhea, reduce the volume of 
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rehydration fluids needed, as well as to shorten the amount and duration of V. 
cholerae excretion in their stool [10]. 
Health care givers are generally discouraged from mass administration of 
antibiotics because it has no known impact and increases the problem of antimicrobial 
resistance. Access to treatment during cholera outbreak is critical and oral rehydration 
should be made available to the communities as well as providing intravenous fluids and 
other essential services on a 24-hour basis. Case fatality ratio (CFR) should remain below 
1% with proper and early treatment [10]. 
Hygiene promotion and social mobilisation 
Health promotion that is in tandem with local culture and beliefs, should advocate 
the adoption of proper hygiene practices including hand-washing with soap, safe food 
handling and storage and proper disposal of faecal waste. To prevent attendees of funeral 
rituals and burial ceremonies from contracting cholera, proper infection prevention and 
control measures must be put in place [10]. 
Sensitization campaigns should be planned during cholera outbreaks with clear 
information provided to the community concerning the potential risks and general 
information about cholera including the symptoms and precautionary measures to take to 
avoid cholera, relevant authorities to report to and where to seek immediate treatment when 






Africa especially Sub-Saharan is marred with conflicts, acute water shortages 
during drought and flooding during rainy seasons. These conditions escalate the cholera 
problem in the region. For example in 2008, a cholera outbreak with unusually high 
mortality occurred in Kenya following  tribal clashes after the results of a disputed 
presidential election [13].According to the WHO, cholera cases reported from Kenya 
increased exponentially over the years. [14].  
In Garissa County an outbreak occurred in April 2017 and later in nine other 
counties (Nairobi, Murang’a, Vihiga, Mombasa, Turkana, Kericho, Nakuru, Kiambu, and 
Narok). These outbreaks occurred in the general population as well as in refugee camps 
such as Hagadera, Dadaab, Dagahaleh and Ifo 2 in Garrissa county and Kakuma and 
Kalobeyei refugee camps in Turkana county [14]. 
In Nairobi county cholera cases occurred interestingly among participants of a 
conference in a high end hotel and another outbreak occurred at a trade fair held at the 
Kenyatta International Convention Centre (KICC) where 146 and 136 cases respectively 
were reported as well as one death [14]. Since December 2014 until 2016, the Republic of 
Kenya has been experiencing continuous large outbreaks of cholera, with a cumulative total 
of 19,739 cases reported (13,291 cases reported in 2015 and 6,448 in 2016)[14]. 
In Zambia in May 2018, Cholera outbreaks occurred in 10 provinces following heavy 
flooding and widespread water shortages and as a result 5,905 suspected cases were 
13 
reported with a case fatality rate of 1.9%. Most of these cases (91.7%) were reported in the 
capital Lusaka [15].  
These characteristics are similar in many other Sub-Saharan Africa countries and 
therefore estimating the economic burden of cholera in this region will be of paramount 
importance in order to plan interventions appropriately, keep policy-makers at all levels 
aware of the economic burden of cholera and aid in mitigation actions required during such 
outbreaks [3] 
 
Study Purpose and Objectives 
Purpose 
The study aims to estimate the economic burden of cholera in Africa in a bid to advise 
countries and partnerships in their efforts for cholera control and elimination.  
Objectives 
 To determine the treatment cost borne by facilities 
 To determine the out of pocket expenses  
 To establish the loss of productivity borne by individual families (patients and 
caregivers) and its economic impact 






This is a retrospective study focusing on 2015 cholera cases as reported to the 
WHO. Countries were classified according the mortality strata as defined by WHO- 
CHOICE (CHoosing Interventions that are Cost-Effective) [16]. 




AFR D Algeria, Angola, Benin, Burkina Faso, Cameroon, Cape 
Verde, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, 
Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, 
Mauritania, Mauritius, Niger, Nigeria, Sao Tome And 
Principe, Senegal, Seychelles, Sierra Leone, Togo 
AFR E Botswana, Burundi, Central African Republic, Congo, Côte 
d'Ivoire, Democratic Republic Of The Congo, Eritrea, 
Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, 
Rwanda, South Africa, Swaziland, Uganda, United Republic 
of Tanzania, Zambia, Zimbabwe 
EMR D Afghanistan, Djibouti, Egypt, Iraq, Morocco, Pakistan, 
Somalia, Sudan, Yemen 
 
Selection criteria 
African countries were listed according to United Nations recognition [17].  
Cholera cases reported by WHO weekly epidemiologic reports  2015 were analyzed [3]. A 
previous study by Mogasale et al classified countries in two groups such that countries who 
15 
reported cholera cases to the WHO in 2015 were put in one group and cholera reporting 
countries from the global burden of disease study by Ali et al were put in the other group.  
In the global burden of disease study, cholera endemicity was defined in terms of a spatial 
regression that predicts the occurrence of cholera in three of the previous five years [3]. 
Data source 
For annual cholera cases and deaths, we used secondary data from WHO weekly 
epidemiological report of 2015 along with estimated annual cholera cases from the disease 
burden study by Ali et al.  
Data on economic cost such as productivity loss, out-of-pocket cost and health 
system costs were obtained through a literature review conducted by Hsiao et al [2]. More 
recent articles from additional searches were also included. 
GDP per capita were sourced from the World Economic Outlook (WEO) Reports by the 
International Monetary Fund (IMF). Data for life expectancy of each country were sourced 




Figure 3 shows health services costs borne by facilities and out-of-pocket 
expenditure as the independent variables which in this case will determine the outcome of 
the study. Intervening variables are represented as loss of productivity by both patients and 
care givers as well as premature deaths. The dependent variable which is the outcome of 
the study is indicated as economic burden.  
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Figure 2: Conceptual Framework 
 
Economic Costs 
Input data to derive the economic costs of cholera are defined by the following: a) 
number of workdays lost due to cholera for patients and caregivers, b) hospitalization rates, 
c) cost-per-case for patients/households and the public health system for hospitalized cases 
and d) cost-per-case for patients/households and the public health system for out-patient 
cases. These data were extracted from previous studies on the economic cost of cholera. 
These studies were identified through a systematic review of the health economics of 
cholera conducted by Hsiao et al in 2018 [2]. Additionally, through searches on PubMed, 
two recent papers not included in the Hsiao (2018) study were included. Data was extracted 
from Ghana, Tanzania, Zambia, Malawi and Mozambique. Due to the limited availability 
Health services 




Loss of productivity 




of the data, the mean value was extrapolated to all countries included in the analysis while 
taking under consideration gross domestic product per capita and the data uncertainty 
represented by confidence interval (CI).  
Loss of productivity by patients and care givers 
Loss of productivity due to illness was estimated based on the average lost work 
days of patients and caregivers during the duration of illness and recuperating period. Lost 
work days of patients and caregivers were recorded separately. Lost work days for Ghana, 
Malawi and Mozambique were extracted directly from their respective sources. Data from 
Tanzania only includes the duration of illness and does not account for loss of productivity 
during the recuperation period. While the study in Zambia did not give an exact average, 
we were able to estimate the average based on the survey results. The ranges of the lost-
days were calculated based on the range derived from the study in Tanzania, where a 
variable of 20% was observed. The lost days were then multiplied by the average income 
per capita (GDP per capita).   
Costs borne by health service delivery facilities 
Service delivery costs were also extracted from the papers for each hospitalized 
and outpatient cases. Health service delivery costs include personnel, medicines, diagnostic 
tools, medical equipment, infrastructure, beds and utilities that patients are not responsible 
for paying. Each of the recorded costs was then converted to the worth of US dollars (US$) 
in 2015. For the conversion, the annual percent changes in world consumer prices as 
established by the IMF were applied. 
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Of the five countries used in this study, Malawi, Tanzania, and Mozambique 
reported health service delivery costs. For countries without reported costs, the outpatient 
service delivery cost estimated through the WHO-CHOICE project was used [18]. The 
WHO-CHOICE outpatient costs for each country was then multiplied by hospitalized and 
outpatient cases to estimate total service delivery costs. 
Out-of-Pocket expenditure 
Out-of-pocket (OOP) costs for hospitalized cases were reported for all five 
countries used in the study. For outpatient cases, only Malawi reported costs.  OOP costs 
can be divided into direct medical and direct non-medical costs. Direct medical costs 
include expenditure accrued by patients for diagnosis, medicine and other costs directly 
related to the treatment of cholera. Direct non-medical costs include resources spent on 
travel to healthcare facility, room and boarding, food and other costs not immediately 
related to treatment. As with health service delivery costs, all costs were converted into the 
amount of US dollars in 2015. For countries that did not report either OOP costs for 
hospitalization or outpatient, the average cost derived from the rest of the reports costs were 
applied.    
Loss of productivity as a result of death 
To estimate the productivity loss due to premature death from cholera, the mean 
age of cholera incidence was derived from a previous study reporting the age distribution 
of cholera by WHO region. Life expectancy at birth for each country was subsequently 
subtracted by the mean age of cholera. Information for life expectancy used the 2015 data 
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provided by the World Bank [19]. In order to convert the years lost to monetary values, 
GDP per capita was multiplied by the number of deaths from cholera and the number of 
productivity years lost per death.  
Hospitalization Rate 
Only the study conducted in Malawi reported hospitalization rate, at 90% 
hospitalized and 10% receiving care for less than 12 hours, which is analogous to outpatient 
care. Other studies included in the analysis were unclear whether all cases were hospitalized 
or only hospitalized cases were accounted for. Since 90-100% hospitalization is considered 
to be highly unusual, the analysis was conducted based on three scenarios: (a) under the 
assumption of 90-100% hospitalization, (b) average of 75% hospitalization and (c) average 
of 55% hospitalization. Assumption (b) was determined based on a previous investment 
case study while assumption (c) was based on results from an economic burden study 
conducted for Asian countries. 
Economic model 
Based on a previous study (Mogasale et al) [8]  we did uncertainty analysis using 
Ersatz an Epigear tool in which we used beta-PERT distribution for cost inputs [20]. This 
enabled us to get the minimum, mean and maximum input parameters. To estimate 95% 
CI, we used Monte Carlo simulation to conduct multivariate sensitivity analysis based on 






The average number of days with loss of income was 5.76 days for patients 
and 3.86 days for care givers. The proportion of cases hospitalized was about 98% 
which was slightly on the higher side. However, due to the fact that there were very 
few outpatient cases the high hospitalization rate was therefore admissible. Mean 
age of death due to cholera was 14.66 years. (Table 4) 
Table 4: Input parameter assumptions used in uncertainty analysis 
Input parameter Mean value Minimum value Maximum 
value 
Source 
Number of days with loss 
of income — cholera 
cases 
5.76 days 4.61 days 6.97 days [2-4, 7, 
9, 21] 
Number of days with loss 
of income — caregivers 
3.86 days 3.09 days 4.64 days [2-4, 7, 
9, 21] 
Proportion of cases 
hospitalized  
0.98 0.90 1.00 [2, 3, 
11] 
Public health service 
delivery costs for 
hospitalized cases  
65.77 US$ 39.83 US$ 85.41 US$ [2, 3, 
11] 
Public health service 
delivery costs for 
outpatient cases 
2.55 US$ 1.54 US$ 3.31 US$ [11] 
Out-of-pocket costs to 
patient and family for 
hospitalization 





[2, 3, 9] 
Out-of-pocket costs to 
patient and family for 
outpatient cases 
5.71 US$ 0.89 US$ 16.15 US$ [2, 3, 9, 
11] 
21 
Input parameter Mean value Minimum value Maximum 
value 
Source 
Age of death due to 
cholera 
14.66 years 1.00 year 75.00 years [2-4, 9, 
11, 21] 
 
The following countries were included in the analysis Angola, Benin, 
Burkina Faso, Burundi, Cameroon, Cape Verde, Central Africa Republic, Chad, 
Comoros, Democratic Republic of Congo, Republic of Congo, Cote D'voire, 
Djibouti, Eritrea, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Guinea-Bissau, 
Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mozambique, 
Namibia, Niger, Nigeria, Rwanda, São Tomé and Principe, Senegal, Sierra Leone, 
Somalia, South Sudan, Sudan, Swaziland, Tanzania, Togo, Uganda, Zambia and 
Zimbabwe  (Annex 2). 
Our analysis included 44 African countries where it was estimated to have 
a total of 1,756,703 cholera cases and 66,416 deaths in 2015. In contrast, the WHO 
cholera report documented 16 countries with 71,176 cases and 937 deaths in Africa. 
Through this analysis we estimated $74.4million (I$186.4million) in out-of-pocket 
expenditure, US$104.2million (I$258.2million) in public health sector costs and $54.0 
million (I$131.9million) in lost productivity of patients and caregivers. The total 
economic burden of cholera in Africa was estimated at $1.9 billion (I$4.6billion) 
Table 5: Economic burden of cholera in Africa  
Economic 
burden 
US$ 2015 (in millions) I$ 2015 (in millions) 




































































The total economic burden of cholera in Africa was estimated at $1.9 billion (I$4.6 
billion). Lost productivity due to premature death due to cholera was estimated to be $1.7 
billion (I$4.7 billion). Productivity loss due to premature death accounted for 87.7% of the 
total economic burden of cholera in Africa. Public health system costs accounted for 5.5%. 
3.9% of the costs were regarded as out-of-pocket expenditure while loss of productivity 
due to illness took 2.9% of the total economic burden of cholera in Africa. 
 
  
Figure 3: Economic burden of cholera in Africa (million $)  
 
Results from a Spearman’s rank correlation coefficient analysis showed which 
input parameter had the most effect on determining the economic burden estimates. The 
results showed that hospitalization costs, for both patient/families and healthcare providers, 
lost days in productivity for both patients and caregivers were among the most sensitive 
parameters in influencing economic burden due to cholera in Africa (Figure 4). 
















Figure 4: Spearman’s RCC: Economic burden of cholera in Africa 
We were able to estimate the economic burden of cholera in Africa as 
summarized in Table 5 below. Countries with high number of cases and deaths such as 






Table 6: Economic burden of cholera in Africa by country 
Country* 
Productivity 



















Angola $1,907,936 $1,033,150 $722,570 $3,663,657 $63,663,745 $67,327,402 
Benin $475,418 $1,037,422 $728,105 $2,240,945 $15,731,108 $17,972,053 
Burkina Faso $396,157 $1,617,053 $1,135,117 $3,148,327 $12,974,961 $16,123,288 
Burundi $156,692 $1,249,419 $877,534 $2,283,645 $4,912,055 $7,195,700 
Cameroon $751,298 $1,319,523 $925,672 $2,996,494 $23,724,394 $26,720,887 
Cape Verde $30,408 $23,909 $16,735 $71,053 $1,149,374 $1,220,427 
Central Africa Rep. $108,400 $719,739 $505,311 $1,333,450 $3,049,372 $4,382,822 
Chad $515,200 $1,278,610 $897,386 $2,691,197 $14,854,844 $17,546,041 
Comoros $29,388 $54,820 $38,473 $122,682 $1,009,791 $1,132,472 
Congo, Democratic Republic $2,199,097 $11,845,306 $8,319,083 $22,363,486 $71,256,767 $93,620,253 
Congo, Rep. $743,759 $847,378 $593,431 $2,184,568 $25,757,376 $27,941,945 
Cote d'voire $2,150,595 $3,618,265 $2,538,438 $8,307,297 $62,606,414 $70,913,711 
Djibouti $46,211 $42,894 $30,093 $119,198 $1,316,422 $1,435,620 
Eritrea $205,069 $1,367,084 $959,968 $2,532,122 $7,146,892 $9,679,013 
Ethiopia $5,160,241 $17,246,028 $12,110,309 $34,516,578 $180,691,570 $215,208,148 
Gabon $414,659 $131,774 $91,759 $638,192 $14,629,121 $15,267,313 
Gambia, The $18,639 $67,413 $47,329 $133,381 $619,459 $752,840 
Ghana $2,357,375 $2,657,060 $3,177,763 $8,192,198 $66,230,704 $74,422,902 
Guinea $338,850 $1,117,790 $784,866 $2,241,506 $11,018,939 $13,260,445 
Guniea-Bissau $43,618 $159,098 $111,721 $314,438 $1,358,111 $1,672,549 
Kenya $4,314,404 $6,976,265 $4,896,247 $16,186,916 $153,926,535 $170,113,450 
Lesotho $185,056 $372,789 $261,637 $819,481 $5,463,085 $6,282,565 
Liberia $132,378 $406,704 $285,618 $824,699 $4,469,317 $5,294,016 
Madagascar $382,756 $2,245,972 $1,576,816 $4,205,543 $13,483,932 $17,689,475 
Malawi $342,005 $2,100,790 $781,796 $3,224,591 $9,436,103 $12,660,694 
Mali $449,747 $1,367,772 $960,038 $2,777,557 $14,184,155 $16,961,712 
Mauritania $185,771 $335,007 $235,059 $755,837 $6,351,655 $7,107,492 
Mozambique $1,013,895 $3,667,667 $2,860,265 $7,541,826 $35,119,696 $42,661,522 
Namibia $815,978 $372,762 $260,801 $1,449,541 $28,116,023 $29,565,564 























Nigeria $16,031,073 $13,827,223 $9,697,933 $39,556,229 $466,078,145 $505,634,374 
Rwanda $383,218 $1,222,526 $858,305 $2,464,050 $13,669,360 $16,133,409 
São Tomé and Principe $11,055 $16,559 $11,617 $39,230 $392,291 $431,521 
Senegal $393,710 $779,750 $547,078 $1,720,538 $14,047,847 $15,768,385 
Sierra Leone $160,091 $627,155 $440,373 $1,227,619 $4,501,181 $5,728,799 
Somalia $95,277 $763,337 $535,462 $1,394,076 $2,460,402 $3,854,478 
South Sudan $961,824 $1,845,870 $1,294,762 $4,102,456 $29,752,181 $33,854,637 
Sudan $1,960,158 $2,714,443 $1,903,839 $6,578,441 $57,284,871 $63,863,312 
Swaziland $206,919 $128,849 $90,292 $426,060 $6,488,561 $6,914,620 
Tanzania $3,725,986 $10,830,527 $4,435,003 $18,991,516 $143,216,936 $162,208,452 
Togo $165,027 $687,795 $482,791 $1,335,614 $5,407,547 $6,743,161 
Uganda $1,548,561 $5,623,684 $3,948,133 $11,120,379 $50,464,551 $61,584,929 
Zambia $999,924 $1,726,815 $625,837 $3,352,577 $32,148,903 $35,501,480 
Zimbambwe $1,193,214 $1,968,631 $1,381,006 $4,542,850 $39,360,526 $43,903,376 
Total $53,986,967 $109,855,395 $74,255,223 $238,097,584 $1,728,656,868 $1,966,754,452 
 
Limitations of the study 
The study has a number of limitations including the following: 
1) Insufficient data – most countries under reported or had not reported cholera cases 
to the WHO at all and therefore we extrapolated data from the countries that 
reported to the WHO in 2015 based on the assumption that the trends were the 
same across Africa. Therefore, this could result in underestimation of the economic 
burden. 
2) Hospitalization rate – Hospitalization rate which directly influenced 
hospitalization costs for both patients and caregivers was unusually high which 
would pendulum the economic burden due to cholera to the upward trajectory. 
Thus scenario analysis was done (we used scenario 1) to determine the lowest 






Using Monte Carlo simulation economic model, we estimated the total economic 
burden of cholera in Africa at $1.9 billion. The brunt of the economic burden was borne by 
productivity loss due to premature death, resultant from the low mean age of cholera death 
of 14.66 years. The countries that bears the greatest of the economic burden of cholera are 
Nigeria, Ethiopia, Kenya, Congo DR and Tanzania. We recommend these countries to 
engage decisively in evidence based research on which cholera control interventions would 
be most appropriate for them and allocate more resources towards cholera prevention 
















Abstract in Korean 
 
전세계적으로 콜레라에 대한 질병의 부담이 지속되고 있으며 이는 저소득 
국가들에서 꾸준히 높게 나타나고 있으며 특히 아프리카에서 가장 많은 영향을 
받고있다. 높은 사망률 (case fatality ratio, CFR)을 수반한 고질적이고 심각한 발병은 
열악한 물과 위생환경으로 인해 본 대륙을 지속적으로 뒤흔들고 있다. 이러한 
발병은 만연한 내부 및 지역간 갈등으로 인해 수많은 난민들과 충분한 위생시설이 
부족한 난민촌의 환경에 의해 발생한다. 또한 장마철에 따른 가뭄과 홍수에 의해 
발병이 되기도 한다. 2015년 세계보건기구 (World Health Organization, WHO) 에 
보고된 콜레라 환자 17만 2464명 가운데 아프리카 지역이 55.8%를 차지했다. 본 
연구는 콜레라 발병 국가의 콜레라 예방 프로그램에 더 많은 자원을 할당할 뿐 
아니라, 콜레라 예방 프로그램을 시행하기 위해 필요한 준비 수준을 평가하기 위해 
아프리카 내 콜레라의 경제적 부담을 추산하는 것을 목표로 한다. 
 
이를 위해 의료시설 부담 치료 비용, 환자 또는 가족 부담 치료비, 환자본인 및 
간병인의 생산성 손실과 치료의 비용효과성과 같은 경제적 입력변수를 평가한다. 
연구에 포함된 국가들은 소득별 및 WHO의 사망층으로 구분되었다. 콜레라 
발병사례는 2015년에 WHO에 보고된 수치를 사용하였다. 그러나 부정적인 경제적 
영향을 우려하여 과소신고 될 수 있는 점을 감안하여 2015년에 발표된 Ali 외 
연구진의 콜레라 질병부담 연구 결과도 사용하였다.  
 
연구결과 2015년 총 175만 6703명의 발병자와 6만 6416명의 사망자가 44개 
아프리카 국가에서 집계되었다. 대조적으로, WHO 콜레라 보고서는 아프리카에서 
71,176명의 발병자와 937명의 사망자를 16개국에서 기록했다. 이 분석을 통해 
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환자 부담 비용 금액이 미화 7,440만 달러, 공공 의료 부문 비용은 1억 420만 달러, 
환자와 간병인의 생산성 손실을  5,400만 달러로 추산했다. 또한 콜레라에 의한 
조기 사망으로 인한 생산성 손실은 약 17억 달러로 추산되었다. 전체 경제적 
부담금액은 약 19억 달러로 추산되었다. 
 
본 연구와 같은 콜레라 경제적 부담의 추정에 관한 연구로 인해 정책 입안자들에게 
질병의 예방, 탐지, 대응, 통제와 관련하여 정보에 입각한 결정을 내릴 수 있는 
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Annex 1: COUNTRY CLASSIFICATION 
ISO Country Region Sub-region WHO Stratum Sanitation MDG Progress Water MDG Progress Economic Classification
AFG Afghanistan Asia Southern Asia EMR-D Limited or no progress Good progress LOW-INCOME ECONOMIES ($995 OR LESS) 
AGO Angola Africa Middle Africa AFR-D Good progress Limited or no progressLOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
BGD Bangladesh Asia Southern Asia SEAR-D Good progress Met target LOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
BEN Benin Africa Western Africa AFR-D Limited or no progress Met target LOW-INCOME ECONOMIES ($995 OR LESS) 
BFA Burkina Faso Africa Western Africa AFR-D Limited or no progress Met target LOW-INCOME ECONOMIES ($995 OR LESS) 
BDI Burundi Africa Eastern Africa AFR-E Limited or no progress Moderate progress LOW-INCOME ECONOMIES ($995 OR LESS) 
CMR Cameroon Africa Middle Africa AFR-D Limited or no progress Met target LOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
TCD Chad Africa Middle Africa AFR-D Limited or no progress Moderate progress LOW-INCOME ECONOMIES ($995 OR LESS) 
COD Congo, Dem. Rep. Africa Middle Africa AFR-E Limited or no progress Limited or no progressLOW-INCOME ECONOMIES ($995 OR LESS) 
COG Congo, Rep. Africa Middle Africa AFR-E N/A N/A LOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
CIV Côte d’Ivoire Africa Western Africa AFR-E Limited or no progress Moderate progress LOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
DJI Djibouti Africa Eastern Africa EMR-D N/A N/A LOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
DOM Dominican Republic Americas Caribbean AMR-B Met target Met target UPPER-MIDDLE-INCOME ECONOMIES ($3,896 TO $12,055) 
ERI Eritrea Africa Eastern Africa AFR-E Moderate progress Met target LOW-INCOME ECONOMIES ($995 OR LESS) 
ETH Ethiopia Africa Eastern Africa AFR-E Met target Met target LOW-INCOME ECONOMIES ($995 OR LESS) 
GHA Ghana Africa Western Africa AFR-D Met target Limited or no progressLOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
GIN Guinea Africa Western Africa AFR-D Limited or no progress Met target LOW-INCOME ECONOMIES ($995 OR LESS) 
GNB Guinea-Bissau Africa Western Africa AFR-D Good progress Met target LOW-INCOME ECONOMIES ($995 OR LESS) 
HTI Haiti Americas Caribbean AMR-D Met target Met target LOW-INCOME ECONOMIES ($995 OR LESS) 
IND India Asia Southern Asia SEAR-D Good progress Met target LOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
IRN Iran, Islamic Rep. Asia Southern Asia EMR-B Met target Good progress UPPER-MIDDLE-INCOME ECONOMIES ($3,896 TO $12,055) 
IRQ Iraq Asia Western Asia EMR-D Limited or no progress Limited or no progressUPPER-MIDDLE-INCOME ECONOMIES ($3,896 TO $12,055) 
KEN Kenya Africa Eastern Africa AFR-E Moderate progress Good progress LOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
LBR Liberia Africa Western Africa AFR-D Limited or no progress Good progress LOW-INCOME ECONOMIES ($995 OR LESS) 
MWI Malawi Africa Eastern Africa AFR-E Moderate progress Met target LOW-INCOME ECONOMIES ($995 OR LESS) 
MYS Malaysia Asia Southeastern Asia Wpr-B Met target Met target UPPER-MIDDLE-INCOME ECONOMIES ($3,896 TO $12,055) 
MLI Mali Africa Western Africa AFR-D Limited or no progress Met target LOW-INCOME ECONOMIES ($995 OR LESS) 
MOZ Mozambique Africa Eastern Africa AFR-E Met target Good progress LOW-INCOME ECONOMIES ($995 OR LESS) 
MMR Myanmar Asia Southeastern Asia SEAR-D Limited or no progress Moderate progress LOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
NAM Namibia Africa Southern Africa AFR-E Met target Met target UPPER-MIDDLE-INCOME ECONOMIES ($3,896 TO $12,055) 
NPL Nepal Asia Southern Asia SEAR-D Limited or no progress N/A LOW-INCOME ECONOMIES ($995 OR LESS) 
NER Niger Africa Western Africa AFR-D Good progress Met target LOW-INCOME ECONOMIES ($995 OR LESS) 
NGA Nigeria Africa Western Africa AFR-D Limited or no progress Good progress LOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
PAK Pakistan Asia Southern Asia EMR-D Limited or no progress Met target LOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
PNG Papua New Guinea Oceania Melanesia Wpr-B Met target Good progress LOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
PHL Philippines Asia Southeastern Asia Wpr-B Met target Met target LOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
SLE Sierra Leone Africa Western Africa AFR-D N/A N/A LOW-INCOME ECONOMIES ($995 OR LESS) 
SOM Somalia Africa Eastern Africa EMR-D N/A N/A LOW-INCOME ECONOMIES ($995 OR LESS) 
SSD South Sudan Africa Eastern Africa Met target Met target LOW-INCOME ECONOMIES ($995 OR LESS) 
SDN Sudan Africa Northern Africa EMR-D N/A N/A LOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
TZA Tanzania Africa Eastern Africa AFR-E Met target Limited or no progressLOW-INCOME ECONOMIES ($995 OR LESS) 
THA Thailand Asia Southeastern Asia SEAR-B Limited or no progress Limited or no progressUPPER-MIDDLE-INCOME ECONOMIES ($3,896 TO $12,055) 
TGO Togo Africa Western Africa AFR-D Limited or no progress Good progress LOW-INCOME ECONOMIES ($995 OR LESS) 
UGA Uganda Africa Eastern Africa AFR-E N/A Met target LOW-INCOME ECONOMIES ($995 OR LESS) 
YEM Yemen, Rep. Asia Western Asia EMR-D N/A N/A LOW-INCOME ECONOMIES ($995 OR LESS) 
ZMB Zambia Africa Eastern Africa AFR-E Limited or no progress Moderate progress LOWER-MIDDLE-INCOME ECONOMIES ($996 TO $3,895) 
ZWE Zimbabwe Africa Eastern Africa AFR-E Limited or no progress Limited or no progressLOW-INCOME ECONOMIES ($995 OR LESS) 
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Annexes 2: GDP per capita in USD 2015  
Country GDP per capita in USD 2015 
GDP per capita in INT 
2015 
Angola 3748.32 7,096.60 
Benin 827.84 2,122.24 
Burkina Faso 645.37 1,704.86 
Burundi 305.55 764.20 
Cameroon 1,326.97 3,442.73 
Cape Verde 3414.56 6,415.61 
Central Africa Rep. 349.17 750.78 
Chad 955.73 2,191.74 
Comoros 1,352.13 2,663.85 
Congo Democratic Republic 497.32 867.09 
Congo, Rep. 1,761.32 6,089.64 
Cote d'voire 1,426.46 3,444.45 
Djibouti 1,787.48 4611.19 
Eritrea 352.32 950.23 
Ethiopia 639.30 1,621.71 
Gabon 7,381.75 17,819.56 
Gambia, The 649.51 1,582.20 
Ghana 1,766.01 4,044.41 
Guinea 769.26 1,986.17 
Guniea-Bissau 603.16 1,574.46 
Kenya 1336.88 2,988.07 
Lesotho 1,219.18 3,062.07 
Liberia 710.38 1,309.27 
Madagascar 402.09 1,470.79 
33 
Country GDP per capita in USD 2015 
GDP per capita in INT 
2015 
Malawi 380.60 1220.23 
Mali 751.17 2,053.13 
Mauritania 1,194.31 3,975.79 
Mozambique 547.24 1237.02 
Namibia 5,032.89 11,160.38 
Niger 360.85 964.84 
Nigeria 2,730.43 6,072.48 
Rwanda 728.08 1,895.11 
São Tomé and Principe 1,595.86 3,086.03 
Senegal 1,218.76 3,205.89 
Sierra Leone 588.23 1,416.37 
Somalia 483.36  
South Sudan 1154.80 2039.75 
Sudan 2486.75 4552.00 
Swaziland 3641.41 9899.29 
Tanzania 947.93 2,791.02 
Togo 570.68 1,566.99 
Uganda 709.02 1,868.55 
Zambia 1332.19 3927.76 







Annex 2: Global burden of disease 
 
Source: Institute for Health Metrics and Evaluation (IHME) 
35 
 
Annex 3: Africa Region Burden of disease 
 
Source: Institute for Health Metrics and Evaluation (IHME)
36 
 
Annex 4: Out patient costs for cholera case in Africa 
  
Results in US 
Dollars, 2008 
Results in US 
Dollars, 2009 





























Angola 6.68 8.25 6.85 8.45 7.10 8.76 7.93 
AFR-
D 
Benin  1.41 1.74 1.44 1.78 1.50 1.85 1.67 
AFR-
D 
Burkina Faso 1.14 1.41 1.17 1.44 1.21 1.49 1.35 
AFR-
E 
Burundi 0.31 0.38 0.32 0.39 0.33 0.41 0.37 
AFR-
D 
Cameroon 2.09 2.59 2.15 2.65 2.22 2.75 2.49 
AFR-
D 
Cape Verde 5.47 6.76 5.61 6.92 5.81 7.18 6.49 
AFR-
E 
Central Africa Republic 0.91 1.12 0.93 1.15 0.96 1.19 1.08 
AFR-
D 
Chad 1.40 1.73 1.43 1.77 1.49 1.84 1.66 
AFR-
D 





0.40 0.50 0.41 0.51 0.43 0.53 0.48 
AFR-
E 
Congo, Rep 4.68 5.78 4.80 5.92 4.97 6.14 5.56 
AFR-
E 
Cote d'voire 2.00 2.48 2.05 2.54 2.13 2.63 2.38 
EMR-
D 
Djibouti 1.98 2.44 2.02 2.50 2.10 2.59 2.34 
AFR-
E 
Eritrea 0.64 0.79 0.65 0.81 0.68 0.84 0.76 
AFR-
E 
Ethiopia 0.62 0.77 0.64 0.79 0.66 0.82 0.74 
AFR-
D 
Gabon 13.28 16.40 13.61 16.80 14.11 17.42 15.76 
AFR-
D 
Gambia, The 0.90 1.11 0.92 1.14 0.96 1.18 1.07 
AFR-
D 
Ghana 1.29 1.59 1.32 1.63 1.37 1.69 1.53 
AFR-
D 
Guinea 0.73 0.90 0.75 0.92 0.77 0.96 0.86 
AFR-
D 
Guniea-Bissau 0.60 0.74 0.62 0.76 0.64 0.79 0.71 
AFR-
E 
Kenya 1.40 1.73 1.44 1.77 1.49 1.84 1.66 
AFR-
E 
Lesotho 1.42 1.75 1.45 1.79 1.51 1.86 1.68 
AFR-
D 
Liberia 0.48 0.59 0.49 0.61 0.51 0.63 0.57 
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Results in US 
Dollars, 2008 
Results in US 
Dollars, 2009 





























Madagascar 0.93 1.15 0.95 1.18 0.99 1.22 1.10 
AFR-
E 
Malawi 0.54 0.67 0.55 0.68 0.57 0.71 0.64 
AFR-
D 
Mali 1.28 1.58 1.31 1.62 1.36 1.68 1.52 
AFR-
D 
Mauritania 1.81 2.23 1.85 2.28 1.92 2.37 2.14 
AFR-
E 
Mozambique 0.86 1.06 0.88 1.09 0.91 1.13 1.02 
AFR-
E 
Namibia 6.13 7.57 6.28 7.75 6.51 8.04 7.27 
AFR-
D 
Niger 0.73 0.90 0.75 0.92 0.78 0.96 0.87 
AFR-
D 
Nigeria 2.43 3.00 2.49 3.07 2.58 3.18 2.88 
AFR-
E 
Rwanda 0.91 1.12 0.93 1.15 0.96 1.19 1.08 
AFR-
D 
São Tomé and Principe 2.05 2.54 2.10 2.60 2.18 2.69 2.44 
AFR-
D 
Senegal 1.91 2.36 1.96 2.41 2.03 2.50 2.27 
AFR-
D 
Sierra Leone 0.69 0.85 0.71 0.87 0.73 0.91 0.82 
EMR-
D 













South Sudan   0.00 0.00 0.00 0.00 0.00 
EMR-
D 
Sudan 2.41 2.97 2.47 3.05 2.56 3.16 2.86 
AFR-
E 
Swaziland 3.72 4.59 3.81 4.71 3.95 4.88 4.42 
AFR-
E 
Tanzania 0.90 1.11 0.92 1.14 0.96 1.18 1.07 
AFR-
D 
Togo  1.20 1.48 1.23 1.51 1.27 1.57 1.42 
AFR-
E 
Uganda  0.95 1.17 0.97 1.20 1.01 1.25 1.13 
AFR-
E 
Zambia 0.90 1.11 0.92 1.14 0.96 1.18 1.07 
AFR-
E 
Zimbambwe 2.13 2.62 2.18 2.69 2.26 2.79 2.52 
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Results in US 
Dollars, 2008 
Results in US 
Dollars, 2009 






























         
 Results in US Dollars, 2008 
Results in US 
Dollars, 2009 
Results in US 
Dollars, 2010   




















beds)   
EMR-
D           2.19  
          
2.71  
          
2.25  
          
2.77  
          
2.33  
          
2.87  
          
2.60  Somalia 
AFR-
D           2.27  
          
2.81  
          
2.33  
          
2.88  
          
2.41  
          
2.98  








Annex 5: Economic burden inputs 
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Annex 6: GDP per capita in USD 2015 source: IMF 
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